Jacobio Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Jacobio Pharmaceuticals Co., Ltd., explained in plain language.
-
New pill targets 'Undruggable' cancer gene in major trial
Disease control Recruiting nowThis study is testing a new oral drug called JAB-23E73 for people with advanced solid tumors that have a specific genetic change in the KRAS gene. The main goals are to find a safe dose, see how the body processes the drug, and check if it can shrink tumors. It is for adults with…
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:50 UTC
-
New pill targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage study is testing a new oral drug called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shows early signs of helping shrink tumors in cancers like certai…
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for tough cancers: first human test of experimental drug begins
Disease control Recruiting nowThis is an early-stage study to test the safety and find the right dose of a new experimental drug, JAB-8263, in adults with advanced cancers that have not responded to standard treatments. The trial will enroll about 152 people with various advanced solid tumors (like lung or ov…
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Experimental pill targets Cancer's 'Guardian Gene' mutation
Disease control Recruiting nowThis clinical trial is testing an experimental oral medication called JAB-30355 for adults with advanced solid tumors that have a specific genetic mutation called TP53 Y220C. The study aims to determine the safest dose and see if the drug can shrink tumors in patients who have al…
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New pill targets common cancer driver in major trial
Disease control Recruiting nowThis study is testing a new oral drug called JAB-23E73 for adults with advanced solid tumors that have a specific genetic change called a KRAS alteration. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for people whose cancer …
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC